应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
INSM Insmed
交易中 09-20 13:32:28 EDT
74.45
-0.52
-0.70%
最高
75.53
最低
73.83
成交量
115.76万
今开
75.01
昨收
74.97
日振幅
2.26%
总市值
127.93亿
流通市值
126.56亿
总股本
1.72亿
成交额
8,655万
换手率
0.68%
流通股本
1.70亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
Insmed Incorporated2024财年第二财季实现净利润-3.01亿美元,同比减少22.86%
自选股智能写手 · 08-18
Insmed Incorporated2024财年第二财季实现净利润-3.01亿美元,同比减少22.86%
Insmed Incorporated盘中异动 大幅上涨5.04%报77.88美元
自选股智能写手 · 08-17
Insmed Incorporated盘中异动 大幅上涨5.04%报77.88美元
Insmed Incorporated盘中异动 早盘股价大跌5.18%
自选股智能写手 · 08-15
Insmed Incorporated盘中异动 早盘股价大跌5.18%
异动解读 | Insmed公司季度亏损超预期 盘前股价大跌5.62%
异动解读 · 08-09
异动解读 | Insmed公司季度亏损超预期 盘前股价大跌5.62%
BUZZ-季度亏损超预期,Insmed公司业绩下滑
Reuters · 08-08
BUZZ-季度亏损超预期,Insmed公司业绩下滑
Insmed Inc 预计每股亏损1.27美元 - 财报前瞻
Reuters · 08-07
Insmed Inc 预计每股亏损1.27美元 - 财报前瞻
Insmed Incorporated盘中异动 早盘股价大跌5.04%
自选股智能写手 · 08-02
Insmed Incorporated盘中异动 早盘股价大跌5.04%
Insmed Inc 预计每股亏损1.27美元 - 财报前瞻
Reuters · 07-31
Insmed Inc 预计每股亏损1.27美元 - 财报前瞻
Insmed Incorporated盘中异动 股价大涨5.03%
自选股智能写手 · 07-12
Insmed Incorporated盘中异动 股价大涨5.03%
Insmed公司:高盛将目标价从$70上调至$95
智通财经 · 07-09
Insmed公司:高盛将目标价从$70上调至$95
HC Wainwright & Co.:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由70.
智通财经 · 07-08
HC Wainwright & Co.:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由70.
美国研究综述-Civitas Resources、GDS Holdings、Spirit Aerosystems
Reuters · 07-08
美国研究综述-Civitas Resources、GDS Holdings、Spirit Aerosystems
美国研究综述-Civitas Resources、GDS Holdings、Spirit Aerosystems
Reuters · 07-08
美国研究综述-Civitas Resources、GDS Holdings、Spirit Aerosystems
Insmed Inc: TD Cowen将目标价从67美元提高至75美元
智通财经 · 07-08
Insmed Inc: TD Cowen将目标价从67美元提高至75美元
成分股Insmed收涨12.9%领跑,该公司在世界支气管扩张大会(WBC)进一步介绍其肺癌试验性疗法brensocatib,第三阶段ASPEN研究评估了那些非囊性纤维化支气管扩张患者的支气管问题(慢性炎性肺病)。
华尔街见闻 · 07-06
成分股Insmed收涨12.9%领跑,该公司在世界支气管扩张大会(WBC)进一步介绍其肺癌试验性疗法brensocatib,第三阶段ASPEN研究评估了那些非囊性纤维化支气管扩张患者的支气管问题(慢性炎性肺病)。
Insmed Incorporated盘中异动 大幅拉升5.21%报65.23美元
自选股智能写手 · 07-05
Insmed Incorporated盘中异动 大幅拉升5.21%报65.23美元
B of A Securities:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由83.00美元调整至83.
智通财经 · 07-05
B of A Securities:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由83.00美元调整至83.
HC Wainwright & Co.:重申Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由70.
智通财经 · 07-02
HC Wainwright & Co.:重申Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由70.
Truist Securities:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由68.00美元调整至88.
智通财经 · 07-01
Truist Securities:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由68.00美元调整至88.
美国研究综述-AT&T, ATI, 加利福尼亚资源公司
Reuters · 07-01
美国研究综述-AT&T, ATI, 加利福尼亚资源公司
加载更多
公司概况
公司名称:
Insmed
所属市场:
NASDAQ
上市日期:
--
主营业务:
Insmed Incorporated是一家生物制药公司,专注于研发吸入疗法为患者对抗危及生命的肺部疾病。公司主打产品ARIKACE和阿米卡星脂质体吸入剂是一种吸入的抗生疗法,证明抗感染药在治疗肺部重感染疾病时能提升该疗法的效果,安全性阿和便利性。公司于1999年11月29日在英联邦弗吉尼亚州成立。
发行价格:
--
{"stockData":{"symbol":"INSM","market":"US","secType":"STK","nameCN":"Insmed","latestPrice":74.446,"timestamp":1726853547171,"preClose":74.97,"halted":0,"volume":1157642,"delay":0,"floatShares":170000000,"shares":171849103,"eps":-5.439528,"marketStatus":"交易中","marketStatusCode":2,"change":-0.524,"latestTime":"09-20 13:32:28 EDT","open":75.01,"high":75.53,"low":73.8325,"amount":86545234.88506,"amplitude":0.022642,"askPrice":74.5,"askSize":231,"bidPrice":74.43,"bidSize":35,"shortable":3,"etf":0,"ttmEps":-5.439528,"exchange":"NASDAQ","tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1726862400000},"adr":0,"listingDate":959832000000,"adjPreClose":74.97,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":75.3,"preClose":74.97,"latestTime":"09:29 EDT","volume":2381,"amount":179601.92529999997,"timestamp":1726838999999},"postHourTrading":{"tag":"盘后","latestPrice":74.74,"preClose":74.97,"latestTime":"19:55 EDT","volume":22756,"amount":1705973.20196,"timestamp":1726790105570},"volumeRatio":1.217539,"impliedVol":0.6051,"impliedVolPercentile":0.6865},"requestUrl":"/m/hq/s/INSM","defaultTab":"news","newsList":[{"id":"2460273574","title":"Insmed Incorporated2024财年第二财季实现净利润-3.01亿美元,同比减少22.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2460273574","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460273574?lang=zh_cn&edition=full","pubTime":"2024-08-18 00:03","pubTimestamp":1723910595,"startTime":"0","endTime":"0","summary":"8月18日,Insmed Incorporated公布财报,公告显示公司2024财年第二财季净利润为-3.01亿美元,同比减少22.86%;其中营业收入为90.34百万美元,同比增加16.98%,每股基本收益为-1.94美元。从资产负债表来看,Insmed Incorporated总负债17.71亿美元,其中短期债务2.37亿美元,资产负债比为1.03,流动比率为2.71。机构评级:截至2024年8月18日,当前有16家机构对Insmed Incorporated目标价做出预测,其中目标均价为87.50美元,其中最低目标价为72.00美元,最高目标价为103.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800045995a16630&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081800045995a16630&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INSM"],"gpt_icon":0},{"id":"2460124180","title":"Insmed Incorporated盘中异动 大幅上涨5.04%报77.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2460124180","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2460124180?lang=zh_cn&edition=full","pubTime":"2024-08-17 00:07","pubTimestamp":1723824470,"startTime":"0","endTime":"0","summary":"北京时间2024年08月17日00时07分,Insmed Incorporated股票出现波动,股价大幅上涨5.04%。截至发稿,该股报77.88美元/股,成交量146.923万股,换手率0.85%,振幅6.06%。Insmed Incorporated股票所在的生物技术行业中,整体跌幅为0.20%。Insmed Incorporated公司简介:Insmed Inc是一家全球性的生物制药公司,致力于改善严重和罕见疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081700075098e35337&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024081700075098e35337&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0109394709.USD","BK4139","LU0889565916.HKD","INSM"],"gpt_icon":0},{"id":"2459780844","title":"Insmed Incorporated盘中异动 早盘股价大跌5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2459780844","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459780844?lang=zh_cn&edition=full","pubTime":"2024-08-15 22:03","pubTimestamp":1723730619,"startTime":"0","endTime":"0","summary":"北京时间2024年08月15日22时03分,Insmed Incorporated股票出现波动,股价快速下挫5.18%。Insmed Incorporated股票所在的生物技术行业中,整体涨幅为0.70%。其相关个股中,Cingulate Inc.、Scisparc Ltd.、Cingulate Inc C/Wts 10/12/2026 涨幅较大,Cingulate Inc.、Scisparc Ltd.、Altamira Therapeutics Ltd.较为活跃,换手率分别为4996.46%、1842.33%、396.78%,振幅较大的相关个股有Seastar Medical Holding Corp C/Wts 28/10/2027 、Cingulate Inc.、Cingulate Inc C/Wts 10/12/2026 ,振幅分别为103.98%、58.54%、50.00%。Insmed Incorporated公司简介:Insmed Inc是一家全球性的生物制药公司,致力于改善严重和罕见疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815220339a1d472bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240815220339a1d472bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0889565916.HKD","INSM","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"1151349728","title":"异动解读 | Insmed公司季度亏损超预期 盘前股价大跌5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151349728","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151349728?lang=zh_cn&edition=full","pubTime":"2024-08-09 16:06","pubTimestamp":1723190801,"startTime":"0","endTime":"0","summary":"生物制药公司Insmed(INSM)今日盘前股价大跌5.62%,报70.22美元,引发市场广泛关注。分析人士认为,公司新发布的第二季度财报亏损超预期可能是导致股价大跌的主要原因。\n\n财报显示,Insmed第二季度每股亏损1.94美元,超出分析师预期的1.27美元。不过,公司季度收入同比增长17%,达到9034万美元,高于分析师预期的8795万美元。\n\n尽管收入有所增长,但亏损超预期可能会打击投资者对公司盈利前景的信心,从而导致股价下跌。分析人士表示,未来公司需要加大研发投入并控制成本,以实现盈利并重振市场信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"gpt_icon":0},{"id":"2457120093","title":"BUZZ-季度亏损超预期,Insmed公司业绩下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2457120093","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457120093?lang=zh_cn&edition=full","pubTime":"2024-08-08 22:31","pubTimestamp":1723127471,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 8月8日 - ** 生物制药公司 Insmed 股价下跌 1%,报 70.22 美元** 公司报告第二季度每股亏损1.94美元,超出预期** 分析师预期每股亏损 1.27 美元 - LSEG** 然而,该公司的季度收入比去年同期增长了 17%,达到 9034 万美元;分析师预期为 8795 万美元。** 包括本交易日在内,股价上涨了约 129.2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0109394709.USD","INSM","BUZZ","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2457207125","title":"Insmed Inc 预计每股亏损1.27美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2457207125","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457207125?lang=zh_cn&edition=full","pubTime":"2024-08-07 01:48","pubTimestamp":1722966530,"startTime":"0","endTime":"0","summary":" * Insmed公司 将于8月8日公布截至2024年6月30日的财报,预计该公司的季度收入将有所增长。* 根据LSEG的数据,13位分析师的平均预期显示,这家总部位于新泽西州布里奇沃特的公司的营收有望从去年同期的7723万美元增长13.9%,达到8795万美元。* LSEG分析师对Insmed公司的平均预期是每股亏损1.27美元。* 华尔街对 Insmed Inc 的 12 个月目标价中值为 85.00 美元,高于其上一次收盘价 71.19 美元。8月6日 - 上一季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Insmed Inc 预计每股亏损1.27美元 - 财报前瞻","news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"gpt_icon":0},{"id":"2456289170","title":"Insmed Incorporated盘中异动 早盘股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2456289170","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456289170?lang=zh_cn&edition=full","pubTime":"2024-08-02 21:31","pubTimestamp":1722605489,"startTime":"0","endTime":"0","summary":"北京时间2024年08月02日21时31分,Insmed Incorporated股票出现异动,股价急速下跌5.04%。Insmed Incorporated股票所在的生物技术行业中,整体跌幅为0.74%。其相关个股中,Exicure, Inc.、Anew Medical Inc C/Wts 21/06/2029 、Os Therapies Incorporated涨幅较大,Exicure, Inc.、Dermata Therapeutics, Inc.、Cns Pharmaceuticals, Inc.较为活跃,换手率分别为213.97%、40.51%、16.51%,振幅较大的相关个股有Nuvation Bio Inc.、Xencor, Inc.、Molecular Partners Ag,振幅分别为9.01%、8.12%、8.00%。Insmed Incorporated公司简介:Insmed Inc是一家全球性的生物制药公司,致力于改善严重和罕见疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802213130968233c0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240802213130968233c0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0109394709.USD","INSM","LU0320765992.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2455964375","title":"Insmed Inc 预计每股亏损1.27美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2455964375","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2455964375?lang=zh_cn&edition=full","pubTime":"2024-07-31 02:44","pubTimestamp":1722365064,"startTime":"0","endTime":"0","summary":" * Insmed公司 将于8月8日公布截至2024年6月30日的财报,预计该公司的季度收入将有所增长。* 根据LSEG的数据,13位分析师的平均预期显示,这家总部位于新泽西州布里奇沃特的公司的营收有望从去年同期的7723万美元增长13.9%,达到8795万美元。* LSEG分析师对Insmed公司的平均预期是每股亏损1.27美元。* 华尔街对 Insmed Inc 的 12 个月目标价中位数为 85.00 美元,高于其上次收盘价 74.56 美元。7月30日 - 以往季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM"],"gpt_icon":0},{"id":"2450390327","title":"Insmed Incorporated盘中异动 股价大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450390327","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450390327?lang=zh_cn&edition=full","pubTime":"2024-07-12 03:28","pubTimestamp":1720726139,"startTime":"0","endTime":"0","summary":"北京时间2024年07月12日03时28分,Insmed Incorporated股票出现异动,股价快速上涨5.03%。Insmed Incorporated股票所在的生物技术行业中,整体跌幅为0.08%。其相关个股中,Surrozen Inc C/Wts 01/08/2031 、Kazia Therapeutics Limited、Neximmune, Inc.涨幅较大,Neximmune, Inc.、Kazia Therapeutics Limited、Biodexa Pharmaceuticals Plc较为活跃,换手率分别为2378.21%、712.93%、685.55%,振幅较大的相关个股有Neximmune, Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Biodexa Pharmaceuticals Plc,振幅分别为205.40%、149.14%、101.95%。Insmed Incorporated公司简介:Insmed Inc是一家全球性的生物制药公司,致力于改善严重和罕见疾病患者的生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712032859941f6598&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712032859941f6598&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INSM"],"gpt_icon":0},{"id":"2450014997","title":"Insmed公司:高盛将目标价从$70上调至$95","url":"https://stock-news.laohu8.com/highlight/detail?id=2450014997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450014997?lang=zh_cn&edition=full","pubTime":"2024-07-09 18:22","pubTimestamp":1720520528,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4533","LU0106831901.USD","BK4585","INSM","BK4550","LU0320765992.SGD","LU2237443382.USD","BK4127","BK4504","IE0034235188.USD","LU2237443549.SGD","BK4588","LU1668664300.SGD","LU2237443978.SGD","LU0109394709.USD","IE00BSNM7G36.USD","LU2237443622.USD","BK4552"],"gpt_icon":0},{"id":"2449778942","title":"HC Wainwright & Co.:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由70.","url":"https://stock-news.laohu8.com/highlight/detail?id=2449778942","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449778942?lang=zh_cn&edition=full","pubTime":"2024-07-08 18:35","pubTimestamp":1720434938,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","LU0109394709.USD","INSM","LU0320765992.SGD"],"gpt_icon":0},{"id":"2449741743","title":"美国研究综述-Civitas Resources、GDS Holdings、Spirit Aerosystems","url":"https://stock-news.laohu8.com/highlight/detail?id=2449741743","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449741743?lang=zh_cn&edition=full","pubTime":"2024-07-08 14:48","pubTimestamp":1720421334,"startTime":"0","endTime":"0","summary":" 路透7月8日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价,其中包括 Civitas Resources、GDS Holdings 和 Spirit Aerosystems。* Interactive Brokers Group Inc :杰富瑞将目标价从138美元上调至150美元 * LPL Financial Holdings Inc :杰富瑞将预测价值从322美元上调至334美元 * Spirit Aerosystems :摩根大通将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK4504","LU1804176565.USD","LU2265009873.SGD","BK4585","LPLA","LU1363072403.SGD","BK4529","VSTM","BK4563","BK4520","LU1861217088.USD","BTU","LU1201861249.SGD","BK4139","LU0971096721.USD","CIVI","SEDG","SPR","LU0980610538.SGD","LU2087625088.SGD","SCHW","LU0312595415.SGD","GDS","INSM","BK4526","BK4211","BK4589","RJF","PSTL","LU1064131342.USD","HCC","BK4194","LU0011850046.USD","IBKR","X","BK4223","BK4588","BK4516","LU0109394709.USD","BK4581","LU1861220207.SGD","SG9999001077.SGD","LU1668664300.SGD","BK4561","LU2249611893.SGD","FFWM","BK4505","AA","IE0034235188.USD"],"gpt_icon":0},{"id":"2449417457","title":"美国研究综述-Civitas Resources、GDS Holdings、Spirit Aerosystems","url":"https://stock-news.laohu8.com/highlight/detail?id=2449417457","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449417457?lang=zh_cn&edition=full","pubTime":"2024-07-08 14:48","pubTimestamp":1720421334,"startTime":"0","endTime":"0","summary":" 路透7月8日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价,其中包括 Civitas Resources、GDS Holdings 和 Spirit Aerosystems。* Interactive Brokers Group Inc :杰富瑞将目标价从138美元上调至150美元 * LPL Financial Holdings Inc :杰富瑞将预测价值从322美元上调至334美元 * Spirit Aerosystems :摩根大通将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INSM","BK4223","LU1064131342.USD","BTU","PSTL","LU0980610538.SGD","BK4194","BK4581","LU1201861249.SGD","LU1804176565.USD","X","BK4588","LU2265009873.SGD","SCHW","BK4516","LU1668664300.SGD","RJF","LPLA","BK4211","IE0034235188.USD","LU0971096721.USD","FFWM","BK4589","GDS","LU1861220207.SGD","BK4520","BK4505","BK4526","BK4529","LU1363072403.SGD","VSTM","AA","BK4561","LU0109394709.USD","LU1861217088.USD","LU2087625088.SGD","BK4585","LU2249611893.SGD","SG9999001077.SGD","SPR","BK4139","LU0011850046.USD","CIVI","SEDG","HCC","IBKR","BK4213","BK4563","LU0312595415.SGD","BK4504"],"gpt_icon":0},{"id":"2449174327","title":"Insmed Inc: TD Cowen将目标价从67美元提高至75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449174327","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449174327?lang=zh_cn&edition=full","pubTime":"2024-07-08 12:20","pubTimestamp":1720412410,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","BK4207","LU0109394709.USD","LU0320765992.SGD","BK4585","BK4566","INSM","TD"],"gpt_icon":0},{"id":"2449246586","title":"成分股Insmed收涨12.9%领跑,该公司在世界支气管扩张大会(WBC)进一步介绍其肺癌试验性疗法brensocatib,第三阶段ASPEN研究评估了那些非囊性纤维化支气管扩张患者的支气管问题(慢性炎性肺病)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2449246586","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449246586?lang=zh_cn&edition=full","pubTime":"2024-07-06 07:30","pubTimestamp":1720222255,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["LU0320765992.SGD","BK4139","LU0109394709.USD","INSM"],"gpt_icon":0},{"id":"2449260618","title":"Insmed Incorporated盘中异动 大幅拉升5.21%报65.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449260618","media":"自选股智能写手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449260618?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:31","pubTimestamp":1720186310,"startTime":"0","endTime":"0","summary":"北京时间2024年07月05日21时31分,Insmed Incorporated股票出现异动,股价急速拉升5.21%。Insmed Incorporated股票所在的生物技术行业中,整体涨幅为0.39%。Insmed Incorporated公司简介:Insmed Inc是一家全球性的生物制药公司,致力于改善严重和罕见疾病患者的生活。消息层面,截至21时31分,《摩根大通维持Insmed买入评级》资讯为影响Insmed Incorporated的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705213150941f4704&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240705213150941f4704&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INSM"],"gpt_icon":0},{"id":"2449563260","title":"B of A Securities:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由83.00美元调整至83.","url":"https://stock-news.laohu8.com/highlight/detail?id=2449563260","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449563260?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:22","pubTimestamp":1720185726,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0109394709.USD","BK4139","INSM","LU0320765992.SGD"],"gpt_icon":0},{"id":"2448131167","title":"HC Wainwright & Co.:重申Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由70.","url":"https://stock-news.laohu8.com/highlight/detail?id=2448131167","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448131167?lang=zh_cn&edition=full","pubTime":"2024-07-02 18:38","pubTimestamp":1719916716,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["INSM","LU0109394709.USD","LU0320765992.SGD","BK4139"],"gpt_icon":0},{"id":"2448997821","title":"Truist Securities:维持Insmed(INSM.US)评级,由买入调整至买入评级, 目标价由68.00美元调整至88.","url":"https://stock-news.laohu8.com/highlight/detail?id=2448997821","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448997821?lang=zh_cn&edition=full","pubTime":"2024-07-01 20:49","pubTimestamp":1719838179,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765992.SGD","INSM","BK4139","LU0109394709.USD"],"gpt_icon":0},{"id":"2448952768","title":"美国研究综述-AT&T, ATI, 加利福尼亚资源公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2448952768","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2448952768?lang=zh_cn&edition=full","pubTime":"2024-07-01 15:23","pubTimestamp":1719818605,"startTime":"0","endTime":"0","summary":" 路透7月1日 - 华尔街证券分析师周一调整了对几家美国上市公司的评级和目标价,其中包括 AT&T、ATI 和加州资源公司。要闻 * AT&T Inc :摩根大通将其股票列入美国分析师关注名单 * ATI Inc :摩根大通将其股票从美国分析师关注名单中删除 * 加州资源公司 :Gerdes Energy Research将其评级从 \"买入 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4562","BK4139","BK4211","APLS","SPB","RCKT","KNTK","BK4589","IE00BSNM7G36.USD","LU0889565916.HKD","BK4018","CRC","BK4196","BK4588","HXL","CHRS","ELAN","LU1621767737.EUR","LU1621767810.EUR","BK4507","RIVN","ACCD","ATI","LU1621768115.EUR","LU0109394709.USD","NKLA","BK4213","ILMN","BK4187","IE00B19Z3581.USD","T","BK4144","LU0321505439.SGD","PTCT","BK4505","EQT","LU0053671581.USD","NOG","TSHA","WBA","SM","IE00B7SZLL34.SGD","INSM","CENT","LU2065732104.USD","BK4585","BK4561","OVV","BK4207","FCNCA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.insmed.com","stockEarnings":[{"period":"1week","weight":0.0143},{"period":"1month","weight":-0.016},{"period":"3month","weight":0.1027},{"period":"6month","weight":1.8365},{"period":"1year","weight":1.9377},{"period":"ytd","weight":1.4192}],"compareEarnings":[{"period":"1week","weight":0.0213},{"period":"1month","weight":0.022},{"period":"3month","weight":0.0486},{"period":"6month","weight":0.0955},{"period":"1year","weight":0.3017},{"period":"ytd","weight":0.2013}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Insmed Incorporated是一家生物制药公司,专注于研发吸入疗法为患者对抗危及生命的肺部疾病。公司主打产品ARIKACE和阿米卡星脂质体吸入剂是一种吸入的抗生疗法,证明抗感染药在治疗肺部重感染疾病时能提升该疗法的效果,安全性阿和便利性。公司于1999年11月29日在英联邦弗吉尼亚州成立。","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":0.07032},{"month":2,"riseRate":0.393939,"avgChangeRate":0.079495},{"month":3,"riseRate":0.382353,"avgChangeRate":-0.053522},{"month":4,"riseRate":0.411765,"avgChangeRate":0.050726},{"month":5,"riseRate":0.411765,"avgChangeRate":0.070481},{"month":6,"riseRate":0.529412,"avgChangeRate":0.014908},{"month":7,"riseRate":0.470588,"avgChangeRate":0.002456},{"month":8,"riseRate":0.382353,"avgChangeRate":-0.030186},{"month":9,"riseRate":0.558824,"avgChangeRate":0.032066},{"month":10,"riseRate":0.424242,"avgChangeRate":-0.023724},{"month":11,"riseRate":0.636364,"avgChangeRate":0.104946},{"month":12,"riseRate":0.484848,"avgChangeRate":0.050703}],"exchange":"NASDAQ","name":"Insmed","nameEN":"Insmed"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Insmed,INSM,Insmed股票,Insmed股票老虎,Insmed股票老虎国际,Insmed行情,Insmed股票行情,Insmed股价,Insmed股市,Insmed股票价格,Insmed股票交易,Insmed股票购买,Insmed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Insmed(INSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Insmed(INSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}